Hepatitis B virus test – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hepatitis B virus test – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Selgantolimod and NUC Discontinuation in Patients with Chronic Hepatitis B https://clinicaltrials.eu/trial/study-on-the-effects-of-selgantolimod-and-nuc-discontinuation-in-patients-with-chronic-hepatitis-b/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-selgantolimod-and-nuc-discontinuation-in-patients-with-chronic-hepatitis-b/ This clinical trial is focused on studying the treatment of Chronic Hepatitis B (CHB), a liver infection caused by the hepatitis B virus. The study involves several medications: Vemlidy (containing the active substance tenofovir alafenamide), Viread (containing tenofovir disoproxil), Baraclude (containing entecavir), and a new investigational drug called Selgantolimod (also known by its code name GS-9688). These medications are taken orally, either as film-coated tablets or as an oral solution.

The purpose of the study is to explore the effectiveness of stopping the use of nucleos(t)ide analogues (NUC), which are standard treatments for CHB, after treatment with Selgantolimod. The study will compare this approach to the continuous use of NUC over a period of 76 weeks. Participants will be divided into groups, with some continuing their NUC treatment and others stopping it after receiving Selgantolimod. The study aims to see if this new approach can lead to a significant reduction in the virus levels in the body.

Participants will be monitored over the course of the study, which lasts for about 76 weeks. During this time, they will have regular check-ups to assess their health and the levels of the virus in their blood. The study will also look at the overall health-related quality of life of the participants. The goal is to find out if the new treatment strategy can help manage Chronic Hepatitis B more effectively than the current standard of care.

]]> Study on Reducing HIV-HBV Treatment with Darunavir, Ritonavir, and Lamivudine for Patients with Controlled Co-Infection https://clinicaltrials.eu/trial/study-on-reducing-hiv-hbv-treatment-with-darunavir-ritonavir-and-lamivudine-for-patients-with-controlled-co-infection/ Wed, 29 Apr 2026 14:56:14 +0000 https://clinicaltrials.eu/trial/study-on-reducing-hiv-hbv-treatment-with-darunavir-ritonavir-and-lamivudine-for-patients-with-controlled-co-infection/ This clinical trial is focused on studying patients who are co-infected with both the HIV-1 and Hepatitis B viruses. The study aims to evaluate the safety of two different strategies for reducing antiviral treatment in these patients. The medications involved in this study include PREZISTA (darunavir), Norvir (ritonavir), Tivicay (dolutegravir sodium), and Epivir (lamivudine). These medications are used to manage the viral infections and are administered in various forms such as film-coated tablets and oral suspension.

The purpose of the study is to assess the safety of reducing treatment while maintaining control over the Hepatitis B virus in patients who have previously been on continuous triple therapy for their co-infection. The study will last for 96 weeks, during which participants will be monitored to ensure that the viral infections remain under control. Participants will receive either a combination of darunavir boosted with ritonavir and lamivudine, or a combination of dolutegravir sodium and lamivudine. The study will also include a group receiving a placebo for comparison.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment strategies. The main focus will be on ensuring that the Hepatitis B virus remains controlled, while also observing the impact on the HIV-1 virus. The study will also look at the participants’ quality of life and any side effects they may experience. This research is important for understanding how to safely reduce medication in patients with these co-infections while maintaining their health.

]]>